Rheumatology · Clinical trials
Lupus Nephritis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About lupus nephritis — and why its trials are hard
Lupus nephritis is immune-complex-mediated glomerulonephritis affecting up to half of SLE patients and is a leading driver of morbidity, end-stage kidney disease, and death. Classified by ISN/RPS histology (classes I-VI), proliferative (class III/IV) and membranous (class V) forms carry the greatest risk. Traditional induction relied on high-dose corticosteroids plus cyclophosphamide or mycophenolate mofetil, achieving complete renal response in only a minority within a year. The therapeutic landscape shifted markedly in 2020-2021 when two add-on agents met their primary endpoints and won FDA approval: belimumab (BLISS-LN) and the calcineurin inhibitor voclosporin (AURORA 1). Both improved renal response rates when layered onto mycophenolate and steroids, and voclosporin offered rapid proteinuria reduction. Goals of care are preservation of kidney function, achievement of durable complete renal response, and minimization of cumulative steroid exposure. Despite progress, a substantial proportion of patients fail to reach complete response, relapse, or progress, underscoring persistent unmet need for deeper, more durable remission.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Voclosporin (Lupkynis) | 2021 | Add-on to mycophenolate + steroids in active adult lupus nephritis (oral calcineurin inhibitor) | AURORA 1 (phase 3) | Complete renal response at week 52 | 40.8% vs 22.5% placebo (odds ratio 2.65, p<0.001) |
| Belimumab (Benlysta) | 2020 (LN indication) | Add-on to standard therapy (mycophenolate or cyclophosphamide) in active lupus nephritis | BLISS-LN (phase 3) | Primary Efficacy Renal Response (PERR) at week 104 | 43% vs 32% placebo (odds ratio 1.6, p=0.03) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in lupus nephritis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rituximab (anti-CD20) — LUNAR (phase 3, proliferative LN) | Did not significantly improve complete/partial renal response over mycophenolate + steroids at 52 weeks | High placebo-arm response, background immunosuppression, and possible incomplete B-cell depletion; remains used off-label in refractory disease |
| Abatacept (CTLA4-Ig) — ACCESS and companion phase 2/3 LN studies | Failed to show consistent benefit on renal response endpoints | Endpoint definition sensitivity and background therapy effects; no clear separation from control |
| Ocrelizumab (anti-CD20) — BELONG (phase 3, proliferative LN) | Study terminated early; efficacy signal not established amid safety concerns | Excess serious infections led to premature termination before efficacy could be confirmed |
Choosing the right endpoint
Primary endpoints that matter in lupus nephritis trials
- Complete Renal Response (CRR) — UPCR <=0.5, near-normal eGFR, no rescue; primary in AURORA 1
- Primary Efficacy Renal Response (PERR) — Composite renal response used in BLISS-LN at week 104
- Proteinuria reduction (UPCR) — Rapid proteinuria decline is a key early prognostic surrogate
- eGFR preservation — Guards against nephron loss and progression to ESKD
How iNGENū runs lupus nephritis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Lupus Nephritis clinical trials — FAQs
What changed in lupus nephritis treatment recently?
Why did rituximab fail in the LUNAR trial?
What is the treatment goal?
Ready to discuss your lupus nephritis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal